ACTICOR BIOTECH DISCLOSURECurrent Reports (8-K / ad hoc)

Inside Information / Other news releases

1 Paris, France, December 19, 2024 – 06:00 PM CET - ACTICOR BIOTECH (FR0014005OJ5 - ALACT), a clinical stage biopharmaceutical company developing glenzocimab, an innovative drug for the treatment of cardiovascular emergencies, announced today that the Paris Commercial Court has today examined the application for conversion of its receivership into liquidation proceedings. Judgment has been postponed until January 2, 2025, when the court will render its decision. A new press release will be issued at that time. In the meantime, Acticor Biotech remains in receivership proceedings. In view of this judgment, there will be no resumption of trading in Acticor Biotech shares. About ACTICOR BIOTECH ACTICOR BIOTECH, a clinical-stage biopharmaceutical company founded in 2013 from the work of INSERM, is developing glenzocimab, a humanized monoclonal antibody fragment (fab) targeting the GPVI platelet receptor for the treatment of cardiovascular emergencies and acute thrombotic diseases. The main clinical indication being evaluated is acute ischemic stroke, due to the strong need for safer treatments, particularly those that do not increase the risk of bleeding, and its high incidence. In three international clinical trials involving over 600 stroke patients, no significant impact on neurological improvement (mRS score at 3 months) was demonstrated, with the exception of a sub-population of patients with intracerebral haemorrhage, where mortality was significantly reduced by a factor of 3 (p=0.035) (Mazighi et al. 2024). LIBERATE, a Phase 2 clinical trial in the acute phase of myocardial infarction (STEMI), is currently being recruited through an academic partnership with the University of Birmingham (UK). This study aims to demonstrate the efficacy of glenzocimab in reducing the size of myocardial infarction, a critical factor for long-term cardiac function. In all, more than 800 subjects were included in the clinical trials, over 400 of whom were exposed to glenzocimab without safety concerns. The use of glenzocimab in thrombotic diseases is covered by 3 patent families, with an expiry date in 2036 for the first family. ACTICOR BIOTECH also has the right to develop a biomarker for stroke patients. Acticor Biotech is backed by a panel of European and international investors (Mediolanum farmaceutici, Karista, Go Capital,